Developing and evaluating, characterizing rDNA Peptide-based therapeutic agents like Liraglutide, peptide hormone based Insulin (Lispro and Glargine) for the treatment of diabetes. Biochemical (bio-analytical and Bio-assays) , clinical (Pre-clinical Toxicology) and analyzing the biological data.

• Development, optimization, validations of colorimetric, potency and bioassays technology transfer and other characterization parameters required for Heparin, Low Molecular Weight Heparins (LMWH’s), Insulin analogs, calcitonin and liraglutide• Strain development, upstream and downstream processing of insulin analogues (Lispro and glargine) and Liraglutide • Efficient experience in analytical instrumentation, calibration. Expertise in Method development, optimization, qualification, bioanalytical validations and method transfer procedures.• Active participant in the internal and client based external audits.• Exposure to FDA guided audits and regulatory requirements bioequivalence assessmentand clinical trials. • Actively participate in discussions, provide alternative suggestions and workarounds for the issues.

Research on thrombotic disorders includes develop the low molecular weight heparins

Mammalian system Clone development and Expression optimization studies for MAB'sIn Vitro Evaluations• Tissue culture handling techniques including  Maintaining Cultured Cells Sub culturing Adherent,( Trypsinization) Suspension cells  Freezing,thawing,counting Cells with a Hemacytometer • Handling experience with Cell Lines Adherent (HepG2, CHO, CHO-K1, Hek-293, Caco-2) semi adherent (Colo-205) T-cell lineage suspension (CEM-SS, MT-2, MT-4, Molt-4, HuT 78 andSupT1); B-cell lineage (CCL-86) • Viral culture handling and cell based assay development Isolation of peripheral blood mononuclear cells (PBMCs) from donor blood Strong technique skills having isolation, propagation, storage, recovery and determination of TCID50 of HIV-1 genetically distinct subtypes Handling Exp in molecular virology techniques, electrophoresis and PCR  Serological techniques including ELISA (P24) and blotting Evaluating the in-vitro antiviral activity of new chemical entities (NCE) inhibitors includes o In vitro combination activity.o Antiviral activity in the presence of serum proteinso Cytotoxicity and therapeutic indices (TI=TC50/IC50).o cell based and biochemical assays ( integrase, RT, Reporter gene β- galactosidase or luciferase and P24 antigen capture assay)• Enhancement of qualitative data interpretation and writing skills amongst research studies • Excellent abilities to create written scientific reports and protocols, and to communicate results in oral presentations• Good laboratory practice and procedure with safety equipment in BSL-3 when working with potentially infectious micro-organisms (rDNA Regulatory norms)• Hands on GRAPH PAD well versed with Ms-Office & internet applications towards windows and communications skills

Rabies and Foot and Mouth disease virus were grown in culture of BHK-21 suspense adapted celline.the virus is inactivated with Binary Ethylenimine (BEI) and after concentration, purification by Ultrafiltration, formulated with aluminum hydroxide gel and montanide oil as a adjuvant and also filling, labeling and packing of final vaccine